A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

NCT06783816 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphocytic Leukemia
Lymphoma,Non-Hodgkin
Relapsed Refractory Multiple Myeloma

Interventions

DRUG: chimeric antigen receptor gene modified T cells

Sponsor

Shanxi Bethune Hospital